Diolch
Working out what works....

Martin Landray @MartinLandray · 8 Oct 2020

The RECOVERY trial has now answered 3 questions for hospitalised COVID pts:
- HCQ is not effective
- Lopinavir is not effective
- Dexamethasone reduces mortality for patients on oxygen or mechanical ventilators

All 3 results have changed medical practice & benefited patients

BREAKING NEWS: PRINCIPLE trial reports the corticosteroid budesonide is the first widely available, inexpensive drug found to shorten recovery time in non-hospitalised patients with COVID-19. It is now available in UK #primarycare on a case-by-case basis.

principlertrial.org/news/asthma-dr...

....and what doesn’t

Peter Horby @PeterHorby · Dec 14, 2020

New RECOVERY result. In patients hospitalised with COVID-19, azithromycin did not provide any clinical benefit. 28 day mortality (19% vs 19%) (rate ratio 1.00; 95% confidence interval [CI] 0.90-1.12; p=0.99). No effect on secondary outcomes either.
medxivr.org/content/10.110...

Martin Landray @MartinLandray

On the advice of the DMC, recruitment to the convalescent plasma arm of the RECOVERY trial has now closed:

Preliminary analysis: No convincing evidence of worthwhile mortality benefit either overall or in any pre-specified subgroup.

GenOMIC Study @GenomiccStudy · Dec 11, 2020

The GenOMIC study has now found 5 DNA changes that make people susceptible to life-threatening COVID-19. These changes are linked to 5 genes and in some cases lead us directly to therapeutic targets. (3/8)

University of Oxford @UniofOxford

VACCINE UPDATE: New study shows that the #OxfordVaccine offers protection of 76% up to 12 weeks after a single dose, with further data supporting a 4-12 week dosing interval:

Peter Horby @PeterHorby · Nov 19, 2020

🔥 news on tocilizumab treatment in critically ill COVID-19 patients-
REMMap-CAP declaring benefit twitter.com/remap_cap/stat...
COVID19 research delivery

94 COVID19 studies set up and open

32 COVID19 UPH Studies
36,500 Welsh Participants

112 patients
8 sites
1,251 patients
6 sites
282 patients

3 Vaccine Trials
(2 in set up)

All studies

15 days to open to recruitment
(UPH studies only)

7.5 days (median) from opening
to recruitment of 1st patient
(UPH studies only)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15</td>
<td>Research and Innovation in health and care: learning from the pandemic</td>
<td>Professor Kieran Walshe, Director HCRW</td>
</tr>
<tr>
<td>13:35</td>
<td>UK Vision for Clinical Research</td>
<td>Carys Thomas, Welsh Government</td>
</tr>
<tr>
<td>14:15</td>
<td>Participant in Research Experience Survey</td>
<td>Dr Andi Skilton, NIHR</td>
</tr>
<tr>
<td>14:35</td>
<td>Contracting and funding in a national model</td>
<td>Dr Helen Hodgson, Fiona Dunn HCRW</td>
</tr>
<tr>
<td>15:15</td>
<td>Digital Health and Care Wales and the future of research within Wales</td>
<td>Rachael Powell, NWIS</td>
</tr>
<tr>
<td>15:35</td>
<td>The One Wales approach to COVID-19 vaccine research</td>
<td>Dr Andrew Freedman, Dr Orod Osanlou, Principal Investigators</td>
</tr>
<tr>
<td>09:15</td>
<td>Positioning Wales as a key player in the COVID-19 research effort</td>
<td>Felicity Waters, HCRW</td>
</tr>
<tr>
<td>09:45</td>
<td>Supporting the care home community through research during pandemics and beyond</td>
<td>Stephanie Green, ENRICH Cymru</td>
</tr>
<tr>
<td>10:15</td>
<td>Five top tips for communication impact</td>
<td>Ginger Training</td>
</tr>
<tr>
<td>11:05</td>
<td>HRA and Health and Care Research Wales: leading, learning and recovering from COVID</td>
<td>Professor Matt Westmore, HRA</td>
</tr>
</tbody>
</table>